

Table SI. Titres of antibody against herpes viruses during the course treatment with intravenous immunoglobulin

| Day* | | -4 | 3 | 17 | 31 | 59 | |
|---------|------|-----|------|------|------|------|-----|
| HHV-6** | IgG | 320 | 640 | 160 | 320 | 640 | |
| | IgM | <10 | <10 | <10 | <10 | <10 | |
| CMV** | IgG | ND | 53.0 | 32.6 | 32.0 | 34.9 | |
| | IgM | ND | 0.46 | 0.16 | 0.43 | 0.50 | |
| EBV** | VCA | IgG | ND | 160 | 160 | 160 | 160 |
| | | IgM | ND | <10 | <10 | <10 | <10 |
| | EADR | IgG | ND | <10 | <10 | <10 | <10 |
| | | IgM | ND | 80 | 80 | 80 | 80 |

*Number indicates time (days) after the eruption. The time-point when the eruption initiated was designated day 0. Virus titre of the preserved serum is also indicated in the first column at day -4. **Titres of antibody against HHV-6/EBV and CMV were measured by fluorescent antibody method and enzyme immunoassay (negative, <1.0), respectively.

VCA: virus capsid antigen; EADR: early antigen-diffuse and restrict complex; NA: nuclear antigen. ND: not done. IVIG therapy was started from day 3 for successive 5 days.